NY Times Reports on the "Psychedelic Revolution"

This week, The New York Times published a piece on the so-called 'Psychedelic Revolution', saying that:

"Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences."

The piece covers recent major studies on MDMA and Psilocybin and demonstrates the change within the media's attitude towards psychedelics as mental health treatment. This is a welcome change for those of us who have been pleading for a change in the broken drug policy of demonization and criminalization.

However, the piece picks up on nervousness of researchers within this field when they say that "the drive to commercialize the drugs, combined with a growing movement to liberalize existing prohibitions, could prove risky, especially for those with severe psychiatric disorders, and derail the field’s slow, methodical return to mainstream acceptance." So, especially within the midst of more and more funding in this field, we should maintain a scientific approach in the psychedelic revolution and keep patients welfare, rather than potential profits, at the front of our mind.

You can read the full piece here.

For more updates on the latest psychedelic news and research, visit the psychedelic health professional network homepage.